New staggered drug combo aims to outsmart lung cancer
NCT ID NCT04163432
First seen Dec 18, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This phase II study tests two staggered schedules of the immunotherapy drug durvalumab combined with standard chemotherapy (pemetrexed and carboplatin) in 43 adults with advanced non-squamous non-small cell lung cancer. The goal is to see if changing the timing of the drugs improves tumor control and keeps side effects manageable. Participants have not received prior chemo-immunotherapy and must have measurable disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (Imfinzi) plus pemetrexed (Alimta) and carboplatin
What this could lead to
If successful, this could point toward a more effective way to schedule immunotherapy and chemotherapy for advanced lung cancer, potentially improving tumor shrinkage and delaying progression.
What could go wrong
This is a small, early-phase trial with only 43 participants, so results may not apply to all patients. The staggered dosing could also increase side effects without improving outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.